Phosphodiesterase type 9 (PDE9) in the human lower urinary tract: An immunohistochemical study

BJU International

Volumn 109, Issue 6, 2012, Pages 934-940

  Nagasaki, Shuji ^a   Nakano, Youichi ^a   Masuda, Mariko ^a   Ono, Katsuhiko ^a   Miki, Yasuhiro ^a   Shibahara, Yukiko ^a   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

cyclic GMP; human; immunohistochemistry; PDE9A protein; urinary tract

Indexed keywords

CYCLIC GMP; MESSENGER RNA; PHOSPHODIESTERASE; PHOSPHODIESTERASE 9; PHOSPHODIESTERASE V; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; AUTOPSY; BLADDER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LASER CAPTURE MICRODISSECTION; MALE; NEUROFILAMENT; PERIKARYON; PRIORITY JOURNAL; PROSTATE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; URETHRA; UROTHELIUM;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; FEMALE; GANGLIA; HUMANS; INFANT; INFANT, NEWBORN; LASER CAPTURE MICRODISSECTION; MALE; MIDDLE AGED; MUSCLE, SMOOTH; PHOSPHORIC DIESTER HYDROLASES; PROSTATE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; URINARY BLADDER; UROTHELIUM; YOUNG ADULT;

EID: 84857648292     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10429.x     Document Type: Article

References (36)

1. Homma Y, Yamaguchi O, Hayashi K,. Epidemiologic survey of lower urinary tract symptoms in Japan. Urology 2006; 68: 560-4 (Pubitemid 44436493)
2. Andersson KE,. Storage and voiding symptoms: pathophysiologic aspects. Urology 2003; 62 (Suppl. 2): 3-10
3. Thomas AW, Abrams P,. Lower urinary tract symptoms, benign prostatic obstruction and the overactive bladder. BJU Int 2000; 85 (Suppl. 3): 57-68 (Pubitemid 30326082)
4. Yoshimura N, Kaiho Y, Miyazato M, et al,. Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol 2008; 377: 437-48
5. Nickel JC, Sander S, Moon TD,. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008; 62: 1547-59
6. Abrams P, Andersson KE,. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007; 100: 987-1006 (Pubitemid 47537675)
7. Emberton M, Zinner N, Michel MC, Gittelman M, Chung MK, Madersbacher S,. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk. BJU Int 2007; 100: 249-53 (Pubitemid 47036593)
8. Smet PJ, Jonavicius J, Marshall VR, de Vente J,. Distribution of nitric oxide synthase-immunoreactive nerves and identification of the cellular targets of nitric oxide in guinea-pig and human urinary bladder by cGMP immunohistochemistry. Neuroscience 1996; 71: 337-48 (Pubitemid 26067004)
9. Bustamante S, Orensanz LM, Recio P, et al,. Functional evidence of nitrergic neurotransmission in the human urinary bladder neck. Neurosci Lett 2010; 477: 91-4
10. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H,. Effects of nitric oxide on human and canine prostates. Urology 1995; 45: 440-6
11. Yoshimura N, Seki S, de Groat WC,. Nitric oxide modulates Ca(2+) channels in dorsal root ganglion neurons innervating rat urinary bladder. J Neurophysiol 2001; 86: 304-11 (Pubitemid 32623235)
12. Kawano T, Zoga V, Kimura M, et al,. Nitric oxide activates ATP-sensitive potassium channels in mammalian sensory neurons: action by direct S-nitrosylation. Mol Pain 2009; 5: 12
13. Yoshimura N, Seki S, Chancellor MB, de Groat WC, Ueda T,. Targeting afferent hyperexcitability for therapy of the painful bladder syndrome. Urology 2002; 59 (Suppl. 1): 61-7 (Pubitemid 34462260)
14. Kedia GT, Uckert S, Jonas U, Kuczyk MA, Burchardt M,. The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol 2008; 26: 603-9
15. Hedlund P,. Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract-is there a basis for pharmacological targeting of cGMP? World J Urol 2005; 23: 362-7 (Pubitemid 43124386)
16. Bender AT, Beavo JA,. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006; 58: 488-520 (Pubitemid 44394910)
17. Fibbi B, Morelli A, Vignozzi L, et al,. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 2010; 7: 59-69
18. Filippi S, Morelli A, Sandner P, et al,. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007; 148: 1019-29
19. Uckert S, Sigl K, Waldkirch ES, et al,. [Significance of phosphodiesterase isoenzymes in the control of human detrusor smooth muscle function. An immunohistochemical and functional study]. Urologe A 2009; 48: 764-9
20. Werkstrom V, Svensson A, Andersson KE, Hedlund P,. Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects. BJU Int 2006; 98: 414-23
21. Tinel H, Stelte-Ludwig B, Hutter J, Sandner P,. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006; 98: 1259-63 (Pubitemid 44721238)
22. Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB,. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 1998; 273: 15559-64 (Pubitemid 28298168)
23. Rentero C, Monfort A, Puigdomenech P,. Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene. Biochem Biophys Res Commun 2003; 301: 686-92 (Pubitemid 36268946)
24. Uckert S, Kuthe A, Jonas U, Stief CG,. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001; 166: 2484-90 (Pubitemid 33065340)
25. Uckert S, Sandner P, Ulbrich E, Stief CG, Kuczyk MA,. Is there a role of the phosphodiesterase type 5 (PDE5) in the control of human detrusor smooth muscle? A functional and molecular biology study. J Urol 2009; 181 (Suppl): 152
26. Lakics V, Karran EH, Boess FG,. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 2010; 59: 367-74
27. Kruse LS, Moller M, Tibaek M, Gammeltoft S, Olesen J, Kruuse C,. PDE9A, PDE10A, and PDE11A expression in rat trigeminovascular pain signalling system. Brain Res 2009; 1281: 25-34
28. van Staveren WC, Glick J, Markerink-van Ittersum M, et al,. Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain. J Neurocytol 2002; 31: 729-41 (Pubitemid 37386661)
29. Gillespie JI, van Koeveringe GA, de Wachter SG, de Vente J,. On the origins of the sensory output from the bladder: the concept of afferent noise. BJU Int 2009; 103: 1324-33
30. Gillespie JI, Markerink-van Ittersum M, de Vente J,. cGMP-generating cells in the bladder wall: identification of distinct networks of interstitial cells. BJU Int 2004; 94: 1114-24 (Pubitemid 39577105)
31. Gillespie JI, Markerink-van Ittersum M, De Vente J,. Endogenous nitric oxide/cGMP signalling in the guinea pig bladder: evidence for distinct populations of sub-urothelial interstitial cells. Cell Tissue Res 2006; 325: 325-32 (Pubitemid 44050798)
32. Fathian-Sabet B, Bloch W, Klotz T, et al,. Localization of constitutive nitric oxide synthase isoforms and the nitric oxide target enzyme soluble guanylyl cyclase in the human bladder. J Urol 2001; 165: 1724-9 (Pubitemid 32410297)
33. Kwan HY, Huang Y, Kong SK, Yao X,. cGMP abolishes agonist-induced [Ca(2+)](i) oscillations in human bladder epithelial cells. Am J Physiol Renal Physiol 2001; 281: F1067-74
34. Sachs D, Cunha FQ, Ferreira SH,. Peripheral analgesic blockade of hypernociception: activation of arginine/NO/cGMP/protein kinase G/ATP-sensitive K+ channel pathway. Proc Natl Acad. Sci USA 2004; 101: 3680-5 (Pubitemid 38338254)
35. Mixcoatl-Zecuatl T, Flores-Murrieta FJ, Granados-Soto V,. The nitric oxide-cyclic GMP-protein kinase G-K+ channel pathway participates in the antiallodynic effect of spinal gabapentin. Eur J Pharmacol 2006; 531: 87-95 (Pubitemid 43202219)
36. Almeida CB, Traina F, Lanaro C, et al,. High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils. Br J Haematol 2008; 142: 836-44